 CARMIEL, Israel, April 28, 2021 PRNewswire -- Protalix BioTherapeutics, Inc. NYSE American: PLX TASE:PLX, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today provided an update regarding the Complete Response Letter CRL received from the U.S. Food and Drug Administration FDA regarding the Biologics License Application BLA seeking accelerated approval of pegunigalsidase alfa PRX102 for the proposed treatment of adult patients with Fabry disease. Receipt of the CRL was announced earlier today. 